Literature DB >> 31110144

Financial relationships between neurologists and industry: The 2015 Open Payments database.

Aditi Ahlawat1, Pushpa Narayanaswami2.   

Abstract

OBJECTIVE: To analyze research and nonresearch payments from the pharmaceutical and device industry to neurologists in 2015 using the Centers for Medicare and Medicaid Services (CMS) Open Payments Database.
METHODS: In this retrospective database analysis, we computed the percentage of neurologists in the United States receiving payments, the median/mean payments per neurologist, payment categories, regional trends, and sponsors. We computed the number of practicing neurologists from the Association of American Medical Colleges State Physician Workforce Data Book, 2015.
RESULTS: In 2015, approximately 96% of US neurologists received nonresearch payments totaling $93,920,993. The median payment per physician was $407. The highest proportion of neurologists (24%) received between $1,000 and $10,000. Food and beverage was the most frequent category (83% of the total number of payments). The highest amount was paid for serving as faculty/speaker for noncontinuing medical education activities (49%). The top sponsor of nonresearch payments was Teva Pharmaceuticals ($16,461,055; 17.5%). A total of 412 neurologists received $2,921,611 in research payments (median $1,132). Multiple sclerosis specialists received the largest proportion ($285,537; 9.7%). Daiichi Sankyo paid the largest amount in research payments ($826,029; 28%).
CONCLUSIONS: The Open Payments program was established to foster transparent disclosure of physician compensations from industry, in response to legislative and public concerns of the effect of conflicts of interest on practice, education, and research. The effects of this program remain unclear and studies of changes in prescribing practices, costs, and other outcomes are necessary. CMS should ensure that incorrect information can be rectified quickly and easily.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31110144     DOI: 10.1212/WNL.0000000000007640

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination.

Authors:  Zachary A Marcum; Ching-Yuan Chang; Douglas Barthold; Holly M Holmes; Wei-Hsuan Lo-Ciganic
Journal:  Neurol Clin Pract       Date:  2021-06

2.  Prescription of Memantine/Donepezil: Influence of Industry Payments?

Authors:  Jens-Peter Reese
Journal:  Neurol Clin Pract       Date:  2021-06

3.  Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019.

Authors:  Anju Murayama; Sae Kamamoto; Hiroaki Saito; Kohki Yamada; Divya Bhandari; Iori Shoji; Hanano Mamada; Moe Kawashima; Erika Yamashita; Eiji Kusumi; Toyoaki Sawano; Binaya Sapkota; Tetsuya Tanimoto; Akihiko Ozaki
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

4.  Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019.

Authors:  Eiji Kusumi; Anju Murayama; Sae Kamamoto; Moe Kawashima; Makoto Yoshida; Hiroaki Saito; Toyoaki Sawano; Erika Yamashita; Tetsuya Tanimoto; Akihiko Ozaki
Journal:  Blood Cancer J       Date:  2022-04-07       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.